ds2

Positive allosteric modulator of δ-subunit containing GABAA receptors

DS21360717 is an effective oral tyrosine kinase inhibitor with anticancer activity and IC50 of 0.49 nM.

DS28120313 is an oral inhibitor of hepcidin production (IC50: 0.093 μM).

DS20362725 is a selective estrogen-related receptor alpha (ERRα) agonist that binds to ERRα and enhances its transcriptional activity while preventing ERRα from binding to its repressor, receptor-interacting protein 140 (RIP140), commonly used in the study of metabolic disorders.

KDS2010 is a potent, highly selective, and reversible MAO-B inhibitor which shows 12,500-fold selectivity over MAO-A. KDS2010 overcomes the disadvantages of the irreversible MAO-B inhibitor and significantly attenuates increased astrocytic GABA levels and astrogliosis, thereby enhancing synaptic transmission, and rescuing learning and memory impairments in APP/PS1 mice.

DS-2969 is a compound that has antibacterial activity.

SC-26196 is an orally active inhibitor of Delta6 desaturase (D6D) with IC50 of 0.2 µM in a rat liver microsomal assay, with antiinflammatory properties.

DS-2248 is a potent Hsp90 inhbitor, currently in phase I trials.

SB1-F-21 is an UCHL1 inhibitor.

Tisolagiline (KDS2010) is a potent, highly selective and reversible MAO-B inhibitor with IC50=8 nM and oral activity for the treatment of Alzheimer's disease and obesity.

DS-22-inf-021, a neuraminidase (NA) inhibitor, exhibits antiviral activity against influenza viruses [1].